MarketsandMarkets forecasts the Metabolomics Market to reach USD 2.38 billion, at a Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period.

Metabolomics plays a vital role in the fields of toxicity testing, biomarker development, drug discovery, and clinical diagnostics. Factors such as the growing demand for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and rising necessity for toxicology testing are driving the growth of the metabolomics market.

Market Growth Opportunity:

Biomarker development;

Metabolomics is used for the identification of new biomarkers through the use of bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for the development of in vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from certain treatments. Moreover, in the near future, the identification of biomarkers related to the safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the metabolomics market.

Browse 188 market data Tables and 42 Figures spread through 286 Pages and in-depth TOC – Request Research Sample Pages: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=900

Market Segmentation in Depth:

On the basis of products & services, the metabolomics market is segmented into metabolomics instruments and bioinformatics tools and services. The metabolomics instruments segment commanded the largest share of the global market. This is mainly due to the ability of these instruments to separate and detect the complex structure of metabolites on a large scale, providing quality results. Furthermore, wide usage of these instruments in research activities, increase in funds for research projects, development of innovative technologies in these tools, and their extensive application in the drug discovery process are fueling the growth of this market.

Based on applications, the biomarker discovery segment accounted for the largest share of the global metabolomics market. The rising prevalence and incidence of chronic diseases such as cardiac diseases, cancer, and diabetes; growing acceptance of cancer diagnostic tests; and scientific progression in discovery technologies are major factors driving market growth in this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900

Geographical Regions Mapped in Report:

North America accounted for the largest share of the metabolomics market, followed by Europe. Easy accessibility to technologically advanced products and the presence of a large number of leading metabolomics manufacturers in the region are driving market growth in North America. Similarly, the rising acceptance of personalized medicines, increasing metabolomics research activities, and growing adoption of technologically advanced products are driving the growth of the North American metabolomics technology market.

Maior Key Players Mapped in Research Report:

Some key players in this market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), LECO Corporation (U.S.), Biocrates Life Sciences AG (Austria), Human Metabolome Technologies, Inc. (Japan), and Waters Corporation (U.S.). These leading players have primarily focused on product launches, acquisitions, agreements, collaborations, partnerships, and expansions for growth in the market.

[286 Pages Report] The Global Metabolomics Market is expected to reach $ 2.38 billion, at a CAGR of 14.6% during the forecast period.

Metabolomics plays a vital role in the fields of toxicity testing, biomarker development, drug discovery, and clinical diagnostics. Factors such as the growing demand for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and rising necessity for toxicology testing are driving the growth of the market. Additionally, the potential for metabolomics to move beyond basic research and into the field of diagnostics, by integrating with other omics technologies such as proteomics and transcriptomics, is also supporting the growth of the market during the forecast period.

This research report segments this Metabolomics Technology Market based on product & Services, application, indication, and region.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900

Metabolomics Market Segmentation: -

Based on products & services, the market is segmented into metabolomics instruments and bioinformatics tools and services. The metabolomics instruments segment commanded the largest share of the global market. This is mainly due to the ability of these instruments to separate and detect the complex structure of metabolites on a large scale, providing quality results.

Based on applications, the biomarker discovery segment accounted for the largest share of the global market. The rising prevalence and incidence of chronic diseases such as cardiac diseases, cancer, and diabetes; growing acceptance of cancer diagnostic tests; and scientific progression in discovery technologies are major factors driving market growth in this segment.

Based on indication, the cancer segment accounted for the largest share of the global market. The large share of this segment can be attributed to the increasing utility of biomarkers in patient stratification and the drug development process and increasing scientific progression in discovery technologies.

 Major Market Drivers in Metabolomics Market:

• Availability of government and private funding
• Increasing pharmaceutical and biotech R&D expenditure
• Technological advancements
• Growing demand for personalized medicine
• Increasing use of metabolomics in toxicology testing
  

Growing demand for personalized medicine;

Personalized medicine is a technology-based and patient-centered customization of diagnosis and treatment evaluation. Recent developments in analytical technologies, such as the emergence of high-resolution mass spectrometry, have provided revolutionary analytical capabilities in metabolomics, offering the detection of more than 10,000 metabolites at a given point of time.

Such developments are opening new opportunities for the utilization of metabolomics in the development of personalized and precision medicine. As metabolomics precisely differentiates between two or more disease phenotypes, it can be applied to identify metabolites and biomarkers related to the perturbation being investigated by providing detailed cellular information. These metabolites can be used to develop personalized prognostic, diagnostic, and treatment approaches for monitoring of disease progression, treatment efficacy, predisposition to drug-related side effects, and potential relapse.

Request Research Sample Pages: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=900

Geographical Analysis in Detailed:

North America is expected to hold the largest market size in the metabolomics market during the forecast period, followed by the European region. On the other hand, the Asia Pacific market is expected to witness the highest growth during the forecast period. Growth in this region can be attributed to the huge demand for metabolomics in drug discovery and biomarker development experiments.

Major Key Players in Metabolomics Market: -

Prominent players in the global market are Thermo Fisher Scientific (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Waters Corporation (U.S.), and Shimadzu Corporation (Japan). Other leading players in this market include Bio-Rad Laboratories (U.S.), Bruker Corporation (U.S.), 

Global Metabolomics Services Market: Information by Product and Service (Chromatography, Metabolomics Bioinformatics Services and Mass Spectrometry), Application (Biomedical and Pharmaceutical, Agriculture and Food) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Metabolomics Services Market Analysis shows market is Growing and is expected to register a CAGR of 7.77%% during the forecast period with a market value of USD 16,291.0 Million till 2025.

 Metabolomics services have been growing at a rapid pace over the last few years. Metabolomics services provide information about the metabolic phenotype by identifying and quantifying the biochemical byproducts of metabolism using different technologically advanced products.

The major key factors driving the market growth are the growing prevalence of diseases such as cancer, neurological disorders, and cardiac diseases across the globe, technological advancements in instrumentation, and increasing application of metabolomics in the life science and biotechnological industry. However, factors such as high cost of instruments and stringent government policies/regulations may hamper the market growth. 

Metabolomics Services Market Key Players

MRFR recognizes the following companies as the Key Players in the Global Metabolomics Services Market—Agilent Technologies, Inc. (US), Waters (US), Bruker (US), TMIC (CANADA), Thermo Fisher Scientific (US), Biocrates Life Sciences AG (AUSTRIA), Creative Proteomics (US), Human Metabolome Technologies America Inc (JAPAN), Shimazdu Corporation (Japan), and Metabolon, INC (US)

Intended Audience

• Medical device companies
• Contract research manufacturing organizations
• Research & development organizations
• Academic institutes

Metabolomics Services Market Key Findings of the Study

The Global Metabolomics Services Market was valued at USD 9,729.0 million in 2018, is estimated to grow at USD 16,291.0 Million by 2025 at a CAGR of 7.77%% during the assessment period

America accounted for the largest share of the global market due to the presence of a huge patient population suffering from chronic diseases.

Based on application, the biomedical and pharmaceutical segment accounted for the largest market share in 2018

Metabolomics Services Market Segment Analysis

The Global Metabolomics Services Market is segmented into product and service and application. Based on product and service, the market has been segmented into chromatography, metabolomics bioinformatics services, and mass spectrometry. On the basis of application, the global metabolomics services market has been segmented into biomedical and pharmaceutical, agriculture, and food.

Browse More Information @ https://www.marketresearchfuture.com/reports/metabolomics-services-market-8435

Metabolomics Services Market Regional Analysis

The Global Metabolomics Services Market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas are expected to hold the largest share of the global metabolomics services market. This is owing to the increasing patient population suffering from cancer, and cardiovascular diseases are boosting the market growth in this region.

The Europe market holds the second-largest position in the global metabolomics services market due to the presence of a large number of companies such as Biocrates Life Sciences AG (Biocrates), Bruker, Waters, and other providing metabolomics services drives the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing region owing to a large number of patient population suffering from chronic disease and increasing demand for treatment for the same.  

The metabolomics services market in the Middle East & Africa accounts for the least market share due to the adequate healthcare infrastructure support accounted for a relatively smaller market share in 2018.